It was the day before Christmas in 2015 and a senior director of national accounts at Novo Nordisk, one of the biggest makers of diabetes medicines, was excited about what Santa might bring.
Eli Lilly had just raised the wholesale price for a diabetes drug, and the employee was hopeful that yet another rival would do the same. ‘Maybe Sanofi will wait until tomorrow morning to announce their price increase…that’s all I want for Christmas,’ the senior director wrote to a colleague. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What’s included? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. This name will appear with your comment
https://www.statnews.com/pharmalot/2021/12/10/medicines-prices-pfizer-patents-pbm/
